Skip to content Skip to footer

Advancing Cancer Innovation from Discovery to Patients

For years, the Asian Fund for Cancer Research Limited (AFCR) has believed that scientific discovery alone is not enough. Promising cancer discoveries need support to move beyond the laboratory toward translation, clinical development and ultimately patient benefit.

Through BIOHK and partnerships across Hong Kong’s biomedical ecosystem, AFCR has brought together researchers, clinicians, entrepreneurs, investors and industry leaders from Asia and around the world to strengthen the connections needed to move innovation forward.

Build Ecosystem for Impacts

Researchers, clinicians and scientific leaders share perspectives on cancer research, precision medicine and emerging biomedical technologies.

Advance Translational Cancer Research

Discussions explore how advances in genomics, biomarkers, artificial intelligence, earlier detection and emerging treatments can move from research toward clinical application.

Connect Research and Entrepreneurship

Scientists, biotechnology companies, entrepreneurs and investors connect around pathways that can advance promising innovations and support future patient benefit.

Build Ecosystem for Impacts

Researchers, clinicians and scientific leaders share perspectives on cancer research, precision medicine and emerging biomedical technologies.

Advance Translational Cancer Research

Discussions explore how advances in genomics, biomarkers, artificial intelligence, earlier detection and emerging treatments can move from research toward clinical application.

Connect Research and Entrepreneurship

Scientists, biotechnology companies, entrepreneurs and investors connect around pathways that can advance promising innovations and support future patient benefit.

The Cancer Research Pathway

Discovery

Translation

Investment

Clinical Development

Patients

The Cancer Research Pathway

Discovery

Translation

Investment

Clinical Development

Patients

Why This Matter

From Early Vision to Emerging Opportunity

AFCR’s Continuing Role in Hong Kong’s Biomedical Innovation Ecosystem
A Look Back: 2022 – 2026

A retrospective on AFCR’s early efforts to convene leaders around translational research, commercialization, capital, clinical development and patient impact – and why this work remains important today.

Explore More from AFCR at BIOHK

AFCR THINK-TANK FORUM AT BIOHK2022

The closed-door Think-Tank Dialogue, A Path Forward in Hong Kong for Cancer Eradication, was organized by the Asian Fund for Cancer Research Limited (AFCR) on 15 December 2022 as part of the BIOHK2022 conference.

Read more

The Asian Fund for Cancer Research Limited supports innovative research and global collaboration designed to accelerate progress against cancer. Your support helps promising discoveries move closer to patients.

Stay Connected